Review



v-plex custom human biomarkers (il-6, il-8, il-10, tnf)  (Meso Scale Diagnostics LLC)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Meso Scale Diagnostics LLC v-plex custom human biomarkers (il-6, il-8, il-10, tnf)
    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; <t>TNF,</t> tumor necrosis factor.
    V Plex Custom Human Biomarkers (Il 6, Il 8, Il 10, Tnf), supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/v+plex+human+biomarker+54+plex+kit/pmc11826443-18-7-9
    Average 90 stars, based on 1 article reviews
    v-plex custom human biomarkers (il-6, il-8, il-10, tnf) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Comparison of Methods for Isolation and Characterization of Total and Astrocyte‐Enriched Extracellular Vesicles From Human Serum and Plasma"

    Article Title: Comparison of Methods for Isolation and Characterization of Total and Astrocyte‐Enriched Extracellular Vesicles From Human Serum and Plasma

    Journal: Journal of Extracellular Biology

    doi: 10.1002/jex2.70035

    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; TNF, tumor necrosis factor.
    Figure Legend Snippet: An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; TNF, tumor necrosis factor.

    Techniques Used: Isolation, Clinical Proteomics, Purification, Western Blot, Concentration Assay, Functional Assay, Binding Assay, Size-exclusion Chromatography

    Comparison of plasma and serum EV for cytokine markers. IL‐6, IL‐8, IL‐10 and TNF from plasma and serum EV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were adjusted to the starting material volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 33, sex – male, BMI – 25.77. AU indicates arbitrary units; IL, Interleukin; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.
    Figure Legend Snippet: Comparison of plasma and serum EV for cytokine markers. IL‐6, IL‐8, IL‐10 and TNF from plasma and serum EV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were adjusted to the starting material volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 33, sex – male, BMI – 25.77. AU indicates arbitrary units; IL, Interleukin; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Techniques Used: Comparison, Clinical Proteomics

    Comparison of plasma and serum AEEV immune biomarkers. IL‐6, IL‐8, IL‐10 and TNF‐alpha from plasma and serum AEEV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were in 250 µL MPER buffer with 1X PIC regardless of starting volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 47, sex – male, BMI – 30.81. AEEV indicates astrocyte‐enriched extracellular vesicles; AU, arbitrary units; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.
    Figure Legend Snippet: Comparison of plasma and serum AEEV immune biomarkers. IL‐6, IL‐8, IL‐10 and TNF‐alpha from plasma and serum AEEV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were in 250 µL MPER buffer with 1X PIC regardless of starting volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 47, sex – male, BMI – 30.81. AEEV indicates astrocyte‐enriched extracellular vesicles; AU, arbitrary units; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Techniques Used: Comparison, Clinical Proteomics

    Related Articles

    Electrochemiluminescence:

    Article Title: Biomarker profiling for risk of future heart failure (HFpEF) development
    Article Snippet: Additional biomarker analysis was performed on baseline and follow up samples to quantify levels of Galectin-3 and hsTroponin I (Architect System, Abbott), sST2 (Presage ST2 Assay, Critical Diagnostics), and IL-6 (electro-chemiluminescence assay, Mesoscale Discovery).

    Article Title: Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults
    Article Snippet: Commercial immunoassay suppliers were R&D Systems (soluble CD163 [sCD163], soluble CD14 [sCD14], soluble receptors for advanced glycation end-products [RAGE], and cystatin C; Minneapolis, MN), Immuno-Biological Laboratories-America (osteopontin; Minneapolis, MN) Meso Scale Discovery (IL-6, fibroblast growth factor [FGF]-1; Rockville, MD), Assaypro (complement C3; St. Charles, MO) and ALPCO (oxidized LDL; Salem, NH).

    Article Title: Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons
    Article Snippet: The following biomarkers were measured at the National Institutes of Allergy and Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemiluminescence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA based assay.

    Article Title: The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
    Article Snippet: High‐sensitivity C‐reactive protein (hsCRP) (Roche, Indianapolis, IN); GlycA (LabCorp, Morrisville, NC); growth differentiation factor 15 (GDF‐15), YKL‐40 (also known as chitinase‐3 like‐protein‐1), MCP‐1, and leptin (R&D Systems, Minneapolis, MN); and IL‐6, intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and NT‐proBNP (MesoScale Discovery, Rockville, MD), were measured by immunoassay.

    Article Title: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Article Snippet: Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

    Article Title: Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study
    Article Snippet: Four biomarkers were measured, namely IGF-1(Immunodiagnostics Systems, East Boldon, United Kingdom, USA), insulin (Immunodiagnostics Systems, East Boldon, United Kingdom), IGFBP-3 (Immunodiagnostics Systems, East Boldon, United Kingdom), and IL-6 (Meso Scale Diagnostics Maryland, USA).

    Article Title: Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
    Article Snippet: hs-CRP, IL-6,TNF-a and PTX3 were measured at baseline exams by the NHLBI Heart Failure Research Network Biomarker Core Laboratory at the University of Vermont using commercially available kits (hs-CRP, Siemens, Indianapolis; IL-6, Meso Scale Discovery, Gaithersbury, MD; TNF-a, EMD Millipore, Billerica, MA; PTX3, R&D systems, Minneapolis, MN).

    Article Title: Sample Processing and Stability for Urine Biomarker Studies
    Article Snippet: Established Meso-Scale Device assay methods were used to measure the urine concentrations of 18 biomarkers: interferon gamma (IFN-ɣ), interleukin (IL)-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNF-α), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), uromodulin (UMOD), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and chitinase-3-like protein 1 (YKL-40).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Biomarker profiling for risk of future heart failure (HFpEF) development
    Article Snippet: Additional biomarker analysis was performed on baseline and follow up samples to quantify levels of Galectin-3 and hsTroponin I (Architect System, Abbott), sST2 (Presage ST2 Assay, Critical Diagnostics), and IL-6 (electro-chemiluminescence assay, Mesoscale Discovery).

    Article Title: Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults
    Article Snippet: Commercial immunoassay suppliers were R&D Systems (soluble CD163 [sCD163], soluble CD14 [sCD14], soluble receptors for advanced glycation end-products [RAGE], and cystatin C; Minneapolis, MN), Immuno-Biological Laboratories-America (osteopontin; Minneapolis, MN) Meso Scale Discovery (IL-6, fibroblast growth factor [FGF]-1; Rockville, MD), Assaypro (complement C3; St. Charles, MO) and ALPCO (oxidized LDL; Salem, NH).

    Article Title: Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons
    Article Snippet: The following biomarkers were measured at the National Institutes of Allergy and Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemiluminescence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA based assay.

    Article Title: The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
    Article Snippet: High‐sensitivity C‐reactive protein (hsCRP) (Roche, Indianapolis, IN); GlycA (LabCorp, Morrisville, NC); growth differentiation factor 15 (GDF‐15), YKL‐40 (also known as chitinase‐3 like‐protein‐1), MCP‐1, and leptin (R&D Systems, Minneapolis, MN); and IL‐6, intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and NT‐proBNP (MesoScale Discovery, Rockville, MD), were measured by immunoassay.

    Article Title: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Article Snippet: Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

    Article Title: Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study
    Article Snippet: Four biomarkers were measured, namely IGF-1(Immunodiagnostics Systems, East Boldon, United Kingdom, USA), insulin (Immunodiagnostics Systems, East Boldon, United Kingdom), IGFBP-3 (Immunodiagnostics Systems, East Boldon, United Kingdom), and IL-6 (Meso Scale Diagnostics Maryland, USA).

    Article Title: Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
    Article Snippet: hs-CRP, IL-6,TNF-a and PTX3 were measured at baseline exams by the NHLBI Heart Failure Research Network Biomarker Core Laboratory at the University of Vermont using commercially available kits (hs-CRP, Siemens, Indianapolis; IL-6, Meso Scale Discovery, Gaithersbury, MD; TNF-a, EMD Millipore, Billerica, MA; PTX3, R&D systems, Minneapolis, MN).

    Article Title: Sample Processing and Stability for Urine Biomarker Studies
    Article Snippet: Established Meso-Scale Device assay methods were used to measure the urine concentrations of 18 biomarkers: interferon gamma (IFN-ɣ), interleukin (IL)-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNF-α), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), uromodulin (UMOD), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and chitinase-3-like protein 1 (YKL-40).

    Clinical Proteomics:

    Article Title: Biomarker profiling for risk of future heart failure (HFpEF) development
    Article Snippet: Additional biomarker analysis was performed on baseline and follow up samples to quantify levels of Galectin-3 and hsTroponin I (Architect System, Abbott), sST2 (Presage ST2 Assay, Critical Diagnostics), and IL-6 (electro-chemiluminescence assay, Mesoscale Discovery).

    Article Title: Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults
    Article Snippet: Commercial immunoassay suppliers were R&D Systems (soluble CD163 [sCD163], soluble CD14 [sCD14], soluble receptors for advanced glycation end-products [RAGE], and cystatin C; Minneapolis, MN), Immuno-Biological Laboratories-America (osteopontin; Minneapolis, MN) Meso Scale Discovery (IL-6, fibroblast growth factor [FGF]-1; Rockville, MD), Assaypro (complement C3; St. Charles, MO) and ALPCO (oxidized LDL; Salem, NH).

    Article Title: Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons
    Article Snippet: The following biomarkers were measured at the National Institutes of Allergy and Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemiluminescence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA based assay.

    Article Title: The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
    Article Snippet: High‐sensitivity C‐reactive protein (hsCRP) (Roche, Indianapolis, IN); GlycA (LabCorp, Morrisville, NC); growth differentiation factor 15 (GDF‐15), YKL‐40 (also known as chitinase‐3 like‐protein‐1), MCP‐1, and leptin (R&D Systems, Minneapolis, MN); and IL‐6, intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and NT‐proBNP (MesoScale Discovery, Rockville, MD), were measured by immunoassay.

    Article Title: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Article Snippet: Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

    Article Title: Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study
    Article Snippet: Four biomarkers were measured, namely IGF-1(Immunodiagnostics Systems, East Boldon, United Kingdom, USA), insulin (Immunodiagnostics Systems, East Boldon, United Kingdom), IGFBP-3 (Immunodiagnostics Systems, East Boldon, United Kingdom), and IL-6 (Meso Scale Diagnostics Maryland, USA).

    Article Title: Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
    Article Snippet: hs-CRP, IL-6,TNF-a and PTX3 were measured at baseline exams by the NHLBI Heart Failure Research Network Biomarker Core Laboratory at the University of Vermont using commercially available kits (hs-CRP, Siemens, Indianapolis; IL-6, Meso Scale Discovery, Gaithersbury, MD; TNF-a, EMD Millipore, Billerica, MA; PTX3, R&D systems, Minneapolis, MN).

    Article Title: Sample Processing and Stability for Urine Biomarker Studies
    Article Snippet: Established Meso-Scale Device assay methods were used to measure the urine concentrations of 18 biomarkers: interferon gamma (IFN-ɣ), interleukin (IL)-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNF-α), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), uromodulin (UMOD), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and chitinase-3-like protein 1 (YKL-40).

    Biomarker Discovery:

    Article Title: Biomarker profiling for risk of future heart failure (HFpEF) development
    Article Snippet: Additional biomarker analysis was performed on baseline and follow up samples to quantify levels of Galectin-3 and hsTroponin I (Architect System, Abbott), sST2 (Presage ST2 Assay, Critical Diagnostics), and IL-6 (electro-chemiluminescence assay, Mesoscale Discovery).

    Article Title: Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults
    Article Snippet: Commercial immunoassay suppliers were R&D Systems (soluble CD163 [sCD163], soluble CD14 [sCD14], soluble receptors for advanced glycation end-products [RAGE], and cystatin C; Minneapolis, MN), Immuno-Biological Laboratories-America (osteopontin; Minneapolis, MN) Meso Scale Discovery (IL-6, fibroblast growth factor [FGF]-1; Rockville, MD), Assaypro (complement C3; St. Charles, MO) and ALPCO (oxidized LDL; Salem, NH).

    Article Title: Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons
    Article Snippet: The following biomarkers were measured at the National Institutes of Allergy and Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemiluminescence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA based assay.

    Article Title: The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
    Article Snippet: High‐sensitivity C‐reactive protein (hsCRP) (Roche, Indianapolis, IN); GlycA (LabCorp, Morrisville, NC); growth differentiation factor 15 (GDF‐15), YKL‐40 (also known as chitinase‐3 like‐protein‐1), MCP‐1, and leptin (R&D Systems, Minneapolis, MN); and IL‐6, intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and NT‐proBNP (MesoScale Discovery, Rockville, MD), were measured by immunoassay.

    Article Title: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Article Snippet: Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

    Article Title: Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study
    Article Snippet: Four biomarkers were measured, namely IGF-1(Immunodiagnostics Systems, East Boldon, United Kingdom, USA), insulin (Immunodiagnostics Systems, East Boldon, United Kingdom), IGFBP-3 (Immunodiagnostics Systems, East Boldon, United Kingdom), and IL-6 (Meso Scale Diagnostics Maryland, USA).

    Article Title: Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
    Article Snippet: hs-CRP, IL-6,TNF-a and PTX3 were measured at baseline exams by the NHLBI Heart Failure Research Network Biomarker Core Laboratory at the University of Vermont using commercially available kits (hs-CRP, Siemens, Indianapolis; IL-6, Meso Scale Discovery, Gaithersbury, MD; TNF-a, EMD Millipore, Billerica, MA; PTX3, R&D systems, Minneapolis, MN).

    Article Title: Sample Processing and Stability for Urine Biomarker Studies
    Article Snippet: Established Meso-Scale Device assay methods were used to measure the urine concentrations of 18 biomarkers: interferon gamma (IFN-ɣ), interleukin (IL)-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNF-α), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), uromodulin (UMOD), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and chitinase-3-like protein 1 (YKL-40).

    Electro Chemiluminescence Assay:

    Article Title: Biomarker profiling for risk of future heart failure (HFpEF) development
    Article Snippet: Additional biomarker analysis was performed on baseline and follow up samples to quantify levels of Galectin-3 and hsTroponin I (Architect System, Abbott), sST2 (Presage ST2 Assay, Critical Diagnostics), and IL-6 (electro-chemiluminescence assay, Mesoscale Discovery).

    Article Title: Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults
    Article Snippet: Commercial immunoassay suppliers were R&D Systems (soluble CD163 [sCD163], soluble CD14 [sCD14], soluble receptors for advanced glycation end-products [RAGE], and cystatin C; Minneapolis, MN), Immuno-Biological Laboratories-America (osteopontin; Minneapolis, MN) Meso Scale Discovery (IL-6, fibroblast growth factor [FGF]-1; Rockville, MD), Assaypro (complement C3; St. Charles, MO) and ALPCO (oxidized LDL; Salem, NH).

    Article Title: Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons
    Article Snippet: The following biomarkers were measured at the National Institutes of Allergy and Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemiluminescence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA based assay.

    Article Title: The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
    Article Snippet: High‐sensitivity C‐reactive protein (hsCRP) (Roche, Indianapolis, IN); GlycA (LabCorp, Morrisville, NC); growth differentiation factor 15 (GDF‐15), YKL‐40 (also known as chitinase‐3 like‐protein‐1), MCP‐1, and leptin (R&D Systems, Minneapolis, MN); and IL‐6, intercellular adhesion molecule 1 (ICAM‐1), vascular cell adhesion molecule 1 (VCAM‐1), and NT‐proBNP (MesoScale Discovery, Rockville, MD), were measured by immunoassay.

    Article Title: Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Article Snippet: Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

    Article Title: Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study
    Article Snippet: Four biomarkers were measured, namely IGF-1(Immunodiagnostics Systems, East Boldon, United Kingdom, USA), insulin (Immunodiagnostics Systems, East Boldon, United Kingdom), IGFBP-3 (Immunodiagnostics Systems, East Boldon, United Kingdom), and IL-6 (Meso Scale Diagnostics Maryland, USA).

    Article Title: Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
    Article Snippet: hs-CRP, IL-6,TNF-a and PTX3 were measured at baseline exams by the NHLBI Heart Failure Research Network Biomarker Core Laboratory at the University of Vermont using commercially available kits (hs-CRP, Siemens, Indianapolis; IL-6, Meso Scale Discovery, Gaithersbury, MD; TNF-a, EMD Millipore, Billerica, MA; PTX3, R&D systems, Minneapolis, MN).

    Article Title: Sample Processing and Stability for Urine Biomarker Studies
    Article Snippet: Established Meso-Scale Device assay methods were used to measure the urine concentrations of 18 biomarkers: interferon gamma (IFN-ɣ), interleukin (IL)-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNF-α), epidermal growth factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), uromodulin (UMOD), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and chitinase-3-like protein 1 (YKL-40).



    Similar Products

    95
    Krishgen Biosystems biomarker il 6 level
    Biomarker Il 6 Level, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/GENLISA+Human+IL-6+ELISA/10__70066_slash_jahm__v13i10__2308-50-1-16
    Average 95 stars, based on 1 article reviews
    biomarker il 6 level - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    90
    Adamis corporation il-6 biomarker
    Il 6 Biomarker, supplied by Adamis corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/il+6+biomarker/pm40609624-196-20-31
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    SAS institute il-6 biomarker
    Transcriptomic metrics of immune resilience (IR): Associations in varied inflammatory contexts. (a) Case study 4 ( GSE188427 ): Respiratory syncytial virus (RSV) infection cohort. Survival‐associated signature‐1 (SAS‐1)/Mortality‐associated signature‐1 (MAS‐1) profiles (key next to panel e) in controls (Ctrl) and RSV patients (days 1, 30, and 180). p , by χ 2 test. (b, c) Case study 5 ( GSE59867 ): ST‐elevation myocardial infarction (STEMI) cohort. (b) SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ; median‐based strata: H, high; L, low) in STEMI patients at admission (Adm), discharge (DC), and post‐discharge ( left ) overall and ( right ) by subsequent heart failure (HF) status. p , by χ 2 test. Ext. IR‐degrad., extreme IR‐degraders. (c) Trajectories (mean ± SE) of the readouts (noted in Figure  ) and normalized gene expression (NGE) of transcription factor 7 ( TCF7 ). p , by linear generalized estimating equations. (d, e) Case study 6 ( GSE65218 ): Vitality 90+ study. (d) Left and middle : Distribution of SAS‐1/MAS‐1 profiles and time to death by circulating cell‐free DNA (cfDNA) quartiles (increasing stress). Right , distribution of SAS‐1/MAS‐1 profiles by TCF7 tertiles. p , by χ 2 , log‐rank, and Fisher's exact tests. (e) Median (IQR) levels of cfDNA and readouts by SAS‐1/MAS‐1 profiles. p , by Kruskal‐Wallis for cfDNA and ANOVA for z‐scores. (f–l) Case 7: Cardiovascular diseases (CVD) and mortality in the Framingham Heart Study. (f) Multi‐protection model. (g) Time to death by CVD and inflammaging proxy (Age_IL6 up signature; median‐based strata: H, high; L, low). (h) Age_IL6 up strata by age and SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ). p , by χ 2 test. (i) Time to CVD diagnosis and (j) time to death among people without CVD diagnosis at baseline by SAS‐1/MAS‐1 profiles and Age_IL6 up strata. Grp, group. p in panels g, i and j, by Cox proportional hazards models adjusted for age, sex, smoking status, diabetes, hypertension, and total cholesterol with likelihood ratio test (LRT). (k) Median (IQR) levels of ( top ) Age_IL6 up signature (z‐scores) and ( bottom ) TCF7 (NGE) by groups in panel j. p , by ANOVA for z‐score and Kruskal‐Wallis for TCF7 . (l) Distribution of SAS‐1/MAS‐1 profiles by indicated outcomes (+, present; −, absent). p , by χ 2 test.
    Il 6 Biomarker, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/il+6+cytokine/pmc12266754-295-4-10
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Omics Data Automation il-6 biomarker
    Transcriptomic metrics of immune resilience (IR): Associations in varied inflammatory contexts. (a) Case study 4 ( GSE188427 ): Respiratory syncytial virus (RSV) infection cohort. Survival‐associated signature‐1 (SAS‐1)/Mortality‐associated signature‐1 (MAS‐1) profiles (key next to panel e) in controls (Ctrl) and RSV patients (days 1, 30, and 180). p , by χ 2 test. (b, c) Case study 5 ( GSE59867 ): ST‐elevation myocardial infarction (STEMI) cohort. (b) SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ; median‐based strata: H, high; L, low) in STEMI patients at admission (Adm), discharge (DC), and post‐discharge ( left ) overall and ( right ) by subsequent heart failure (HF) status. p , by χ 2 test. Ext. IR‐degrad., extreme IR‐degraders. (c) Trajectories (mean ± SE) of the readouts (noted in Figure  ) and normalized gene expression (NGE) of transcription factor 7 ( TCF7 ). p , by linear generalized estimating equations. (d, e) Case study 6 ( GSE65218 ): Vitality 90+ study. (d) Left and middle : Distribution of SAS‐1/MAS‐1 profiles and time to death by circulating cell‐free DNA (cfDNA) quartiles (increasing stress). Right , distribution of SAS‐1/MAS‐1 profiles by TCF7 tertiles. p , by χ 2 , log‐rank, and Fisher's exact tests. (e) Median (IQR) levels of cfDNA and readouts by SAS‐1/MAS‐1 profiles. p , by Kruskal‐Wallis for cfDNA and ANOVA for z‐scores. (f–l) Case 7: Cardiovascular diseases (CVD) and mortality in the Framingham Heart Study. (f) Multi‐protection model. (g) Time to death by CVD and inflammaging proxy (Age_IL6 up signature; median‐based strata: H, high; L, low). (h) Age_IL6 up strata by age and SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ). p , by χ 2 test. (i) Time to CVD diagnosis and (j) time to death among people without CVD diagnosis at baseline by SAS‐1/MAS‐1 profiles and Age_IL6 up strata. Grp, group. p in panels g, i and j, by Cox proportional hazards models adjusted for age, sex, smoking status, diabetes, hypertension, and total cholesterol with likelihood ratio test (LRT). (k) Median (IQR) levels of ( top ) Age_IL6 up signature (z‐scores) and ( bottom ) TCF7 (NGE) by groups in panel j. p , by ANOVA for z‐score and Kruskal‐Wallis for TCF7 . (l) Distribution of SAS‐1/MAS‐1 profiles by indicated outcomes (+, present; −, absent). p , by χ 2 test.
    Il 6 Biomarker, supplied by Omics Data Automation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/il+6+biomarker/10__1097_slash_js9__0000000000002358-154-47-10
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    FineTest Biotech Inc il-6 biomarker
    Transcriptomic metrics of immune resilience (IR): Associations in varied inflammatory contexts. (a) Case study 4 ( GSE188427 ): Respiratory syncytial virus (RSV) infection cohort. Survival‐associated signature‐1 (SAS‐1)/Mortality‐associated signature‐1 (MAS‐1) profiles (key next to panel e) in controls (Ctrl) and RSV patients (days 1, 30, and 180). p , by χ 2 test. (b, c) Case study 5 ( GSE59867 ): ST‐elevation myocardial infarction (STEMI) cohort. (b) SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ; median‐based strata: H, high; L, low) in STEMI patients at admission (Adm), discharge (DC), and post‐discharge ( left ) overall and ( right ) by subsequent heart failure (HF) status. p , by χ 2 test. Ext. IR‐degrad., extreme IR‐degraders. (c) Trajectories (mean ± SE) of the readouts (noted in Figure  ) and normalized gene expression (NGE) of transcription factor 7 ( TCF7 ). p , by linear generalized estimating equations. (d, e) Case study 6 ( GSE65218 ): Vitality 90+ study. (d) Left and middle : Distribution of SAS‐1/MAS‐1 profiles and time to death by circulating cell‐free DNA (cfDNA) quartiles (increasing stress). Right , distribution of SAS‐1/MAS‐1 profiles by TCF7 tertiles. p , by χ 2 , log‐rank, and Fisher's exact tests. (e) Median (IQR) levels of cfDNA and readouts by SAS‐1/MAS‐1 profiles. p , by Kruskal‐Wallis for cfDNA and ANOVA for z‐scores. (f–l) Case 7: Cardiovascular diseases (CVD) and mortality in the Framingham Heart Study. (f) Multi‐protection model. (g) Time to death by CVD and inflammaging proxy (Age_IL6 up signature; median‐based strata: H, high; L, low). (h) Age_IL6 up strata by age and SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ). p , by χ 2 test. (i) Time to CVD diagnosis and (j) time to death among people without CVD diagnosis at baseline by SAS‐1/MAS‐1 profiles and Age_IL6 up strata. Grp, group. p in panels g, i and j, by Cox proportional hazards models adjusted for age, sex, smoking status, diabetes, hypertension, and total cholesterol with likelihood ratio test (LRT). (k) Median (IQR) levels of ( top ) Age_IL6 up signature (z‐scores) and ( bottom ) TCF7 (NGE) by groups in panel j. p , by ANOVA for z‐score and Kruskal‐Wallis for TCF7 . (l) Distribution of SAS‐1/MAS‐1 profiles by indicated outcomes (+, present; −, absent). p , by χ 2 test.
    Il 6 Biomarker, supplied by FineTest Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/il+6+cytokine/pm40372306-72-48-49
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Meso Scale Diagnostics LLC v-plex custom human biomarkers (il-6, il-8, il-10, tnf)
    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; <t>TNF,</t> tumor necrosis factor.
    V Plex Custom Human Biomarkers (Il 6, Il 8, Il 10, Tnf), supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/v+plex+human+biomarker+54+plex+kit/pmc11826443-18-7-9
    Average 90 stars, based on 1 article reviews
    v-plex custom human biomarkers (il-6, il-8, il-10, tnf) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher il-6 biomarker
    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; <t>TNF,</t> tumor necrosis factor.
    Il 6 Biomarker, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/il+6+elisa+kit/pm39644356-77-9-10
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Diaclone il-6 biomarker
    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; <t>TNF,</t> tumor necrosis factor.
    Il 6 Biomarker, supplied by Diaclone, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il-6+biomarker/recombinant+human+il+6/pmc11798962-99-17-18
    Average 90 stars, based on 1 article reviews
    il-6 biomarker - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Transcriptomic metrics of immune resilience (IR): Associations in varied inflammatory contexts. (a) Case study 4 ( GSE188427 ): Respiratory syncytial virus (RSV) infection cohort. Survival‐associated signature‐1 (SAS‐1)/Mortality‐associated signature‐1 (MAS‐1) profiles (key next to panel e) in controls (Ctrl) and RSV patients (days 1, 30, and 180). p , by χ 2 test. (b, c) Case study 5 ( GSE59867 ): ST‐elevation myocardial infarction (STEMI) cohort. (b) SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ; median‐based strata: H, high; L, low) in STEMI patients at admission (Adm), discharge (DC), and post‐discharge ( left ) overall and ( right ) by subsequent heart failure (HF) status. p , by χ 2 test. Ext. IR‐degrad., extreme IR‐degraders. (c) Trajectories (mean ± SE) of the readouts (noted in Figure  ) and normalized gene expression (NGE) of transcription factor 7 ( TCF7 ). p , by linear generalized estimating equations. (d, e) Case study 6 ( GSE65218 ): Vitality 90+ study. (d) Left and middle : Distribution of SAS‐1/MAS‐1 profiles and time to death by circulating cell‐free DNA (cfDNA) quartiles (increasing stress). Right , distribution of SAS‐1/MAS‐1 profiles by TCF7 tertiles. p , by χ 2 , log‐rank, and Fisher's exact tests. (e) Median (IQR) levels of cfDNA and readouts by SAS‐1/MAS‐1 profiles. p , by Kruskal‐Wallis for cfDNA and ANOVA for z‐scores. (f–l) Case 7: Cardiovascular diseases (CVD) and mortality in the Framingham Heart Study. (f) Multi‐protection model. (g) Time to death by CVD and inflammaging proxy (Age_IL6 up signature; median‐based strata: H, high; L, low). (h) Age_IL6 up strata by age and SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ). p , by χ 2 test. (i) Time to CVD diagnosis and (j) time to death among people without CVD diagnosis at baseline by SAS‐1/MAS‐1 profiles and Age_IL6 up strata. Grp, group. p in panels g, i and j, by Cox proportional hazards models adjusted for age, sex, smoking status, diabetes, hypertension, and total cholesterol with likelihood ratio test (LRT). (k) Median (IQR) levels of ( top ) Age_IL6 up signature (z‐scores) and ( bottom ) TCF7 (NGE) by groups in panel j. p , by ANOVA for z‐score and Kruskal‐Wallis for TCF7 . (l) Distribution of SAS‐1/MAS‐1 profiles by indicated outcomes (+, present; −, absent). p , by χ 2 test.

    Journal: Aging Cell

    Article Title: The 15‐Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging

    doi: 10.1111/acel.70063

    Figure Lengend Snippet: Transcriptomic metrics of immune resilience (IR): Associations in varied inflammatory contexts. (a) Case study 4 ( GSE188427 ): Respiratory syncytial virus (RSV) infection cohort. Survival‐associated signature‐1 (SAS‐1)/Mortality‐associated signature‐1 (MAS‐1) profiles (key next to panel e) in controls (Ctrl) and RSV patients (days 1, 30, and 180). p , by χ 2 test. (b, c) Case study 5 ( GSE59867 ): ST‐elevation myocardial infarction (STEMI) cohort. (b) SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ; median‐based strata: H, high; L, low) in STEMI patients at admission (Adm), discharge (DC), and post‐discharge ( left ) overall and ( right ) by subsequent heart failure (HF) status. p , by χ 2 test. Ext. IR‐degrad., extreme IR‐degraders. (c) Trajectories (mean ± SE) of the readouts (noted in Figure ) and normalized gene expression (NGE) of transcription factor 7 ( TCF7 ). p , by linear generalized estimating equations. (d, e) Case study 6 ( GSE65218 ): Vitality 90+ study. (d) Left and middle : Distribution of SAS‐1/MAS‐1 profiles and time to death by circulating cell‐free DNA (cfDNA) quartiles (increasing stress). Right , distribution of SAS‐1/MAS‐1 profiles by TCF7 tertiles. p , by χ 2 , log‐rank, and Fisher's exact tests. (e) Median (IQR) levels of cfDNA and readouts by SAS‐1/MAS‐1 profiles. p , by Kruskal‐Wallis for cfDNA and ANOVA for z‐scores. (f–l) Case 7: Cardiovascular diseases (CVD) and mortality in the Framingham Heart Study. (f) Multi‐protection model. (g) Time to death by CVD and inflammaging proxy (Age_IL6 up signature; median‐based strata: H, high; L, low). (h) Age_IL6 up strata by age and SAS‐1/MAS‐1 profiles (H‐L: SAS‐1 high ‐MAS‐1 low ; L‐H: SAS‐1 low ‐MAS‐1 high ). p , by χ 2 test. (i) Time to CVD diagnosis and (j) time to death among people without CVD diagnosis at baseline by SAS‐1/MAS‐1 profiles and Age_IL6 up strata. Grp, group. p in panels g, i and j, by Cox proportional hazards models adjusted for age, sex, smoking status, diabetes, hypertension, and total cholesterol with likelihood ratio test (LRT). (k) Median (IQR) levels of ( top ) Age_IL6 up signature (z‐scores) and ( bottom ) TCF7 (NGE) by groups in panel j. p , by ANOVA for z‐score and Kruskal‐Wallis for TCF7 . (l) Distribution of SAS‐1/MAS‐1 profiles by indicated outcomes (+, present; −, absent). p , by χ 2 test.

    Article Snippet: Pro‐inflammatory biomarkers such as IL‐6 progressively increased from optimal IR (SAS‐1 high ‐MAS‐1 low ) to extreme IR degradation (SAS‐1 low ‐MAS‐1 high ), whereas immunocompetence‐associated and trophic markers such as CD23—a B‐cell marker—exhibited the opposite pattern.

    Techniques: Virus, Infection, Gene Expression, Biomarker Discovery

    An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; TNF, tumor necrosis factor.

    Journal: Journal of Extracellular Biology

    Article Title: Comparison of Methods for Isolation and Characterization of Total and Astrocyte‐Enriched Extracellular Vesicles From Human Serum and Plasma

    doi: 10.1002/jex2.70035

    Figure Lengend Snippet: An overview of isolation methods and characterization for TEV and AEEV. Plasma or serum with and without PK was used to test five TEV isolation methods: precipitation (SBI ExoQuick and LabSpinner ExoPRISM); SEC (SBI SmartSEC and Izon qEV); precipitation + purification (SBI ExoQuick Ultra); Silicon Carbide (Norgen) and dUC. AEEV were immunocaptured with a biotinylated antibody against the astrocyte‐specific GLAST antibody. Characterization steps for TEV and AEEV included detection of tetraspanins (CD63, CD81, CD9), syntenin‐1, Alix and calnexin (western blot analysis); particle concentration and quantification (MRPS); tetraspanin bioassays (MSD) and protein concentrations (BCA). Functional assays include cytokine, astrocyte and immune markers. TEV were compared for EV yield and purity, whilst AEEV were compared for purity and recovery. AEEV indicates astrocyte‐enriched extracellular vesicles; ApoE, apolipoprotein E; BCA, bicinchoninic assay; CD14, cluster of differentiation 14; dUC, differential ultracentrifugation; GFAP, glial fibrillary acidic protein; GLAST, glutamate aspartate transporter; IL‐6, interleukin‐6; LBP, lipopolysaccharide‐binding protein; MRPS, microfluidic resistive pulse sensing; MSD, Meso Scale Discovery; PK, proteinase K; SBI, systems biosciences; SEC, size exclusion chromatography; TEV, total EV; TNF, tumor necrosis factor.

    Article Snippet: V‐PLEX custom human biomarkers (IL‐6, IL‐8, IL‐10, TNF) , Meso Scale Discovery , K151A9H‐2.

    Techniques: Isolation, Clinical Proteomics, Purification, Western Blot, Concentration Assay, Functional Assay, Binding Assay, Size-exclusion Chromatography

    Comparison of plasma and serum EV for cytokine markers. IL‐6, IL‐8, IL‐10 and TNF from plasma and serum EV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were adjusted to the starting material volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 33, sex – male, BMI – 25.77. AU indicates arbitrary units; IL, Interleukin; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Journal: Journal of Extracellular Biology

    Article Title: Comparison of Methods for Isolation and Characterization of Total and Astrocyte‐Enriched Extracellular Vesicles From Human Serum and Plasma

    doi: 10.1002/jex2.70035

    Figure Lengend Snippet: Comparison of plasma and serum EV for cytokine markers. IL‐6, IL‐8, IL‐10 and TNF from plasma and serum EV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were adjusted to the starting material volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 33, sex – male, BMI – 25.77. AU indicates arbitrary units; IL, Interleukin; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Article Snippet: V‐PLEX custom human biomarkers (IL‐6, IL‐8, IL‐10, TNF) , Meso Scale Discovery , K151A9H‐2.

    Techniques: Comparison, Clinical Proteomics

    Comparison of plasma and serum AEEV immune biomarkers. IL‐6, IL‐8, IL‐10 and TNF‐alpha from plasma and serum AEEV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were in 250 µL MPER buffer with 1X PIC regardless of starting volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 47, sex – male, BMI – 30.81. AEEV indicates astrocyte‐enriched extracellular vesicles; AU, arbitrary units; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Journal: Journal of Extracellular Biology

    Article Title: Comparison of Methods for Isolation and Characterization of Total and Astrocyte‐Enriched Extracellular Vesicles From Human Serum and Plasma

    doi: 10.1002/jex2.70035

    Figure Lengend Snippet: Comparison of plasma and serum AEEV immune biomarkers. IL‐6, IL‐8, IL‐10 and TNF‐alpha from plasma and serum AEEV concentrations were measured using V‐PLEX human proinflammatory panel 1 high‐sensitivity assays from MSD. CD9 was measured using R‐PLEX human CD9 (EV) assay. Final concentrations were in 250 µL MPER buffer with 1X PIC regardless of starting volume. AU: Human EV Calibrator Standard 1 (to standard curve) = 1000 AU/L. Sample used: age – 47, sex – male, BMI – 30.81. AEEV indicates astrocyte‐enriched extracellular vesicles; AU, arbitrary units; MSD, Meso Scale Discovery; TNF, tumor necrosis factor.

    Article Snippet: V‐PLEX custom human biomarkers (IL‐6, IL‐8, IL‐10, TNF) , Meso Scale Discovery , K151A9H‐2.

    Techniques: Comparison, Clinical Proteomics